Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
May 22, 2021 at 15:05 PM EDT
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones.